Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12314
Title: Evolving role of tumor antigens for future melanoma therapies.
Authors: Andrews, Miles C;Woods, Katherine;Cebon, Jonathan S;Behren, Andreas
Affiliation: Ludwig Institute for Cancer Research Ltd, Olivia Newton-John Cancer & Wellness Centre, Cancer Immunobiology, Heidelberg, VIC, Australia.
Issue Date: 1-Jun-2014
Citation: Future Oncology (london, England); 10(8): 1457-68
Abstract: Human tumor rejection antigens recognized by T lymphocytes were first defined in the early 1990s and the identification of shared tumor-restricted antigens sparked hopes for the development of a therapeutic vaccination to treat cancer, including melanoma. Despite decades of intense preclinical and clinical research, the success of anticancer vaccines based on these antigens has been limited. While melanoma is a highly immunogenic tumor, the ability to prime immunity with vaccines has not generally translated into objective disease regression. However, with the development of small molecules targeting oncogenic proteins, such as V600-mutated BRAF, and immune checkpoint inhibitors with demonstrable long-lasting clinical benefit, new opportunities for antigen-targeted directed therapies are emerging.
Internal ID Number: 25052755
URI: http://ahro.austin.org.au/austinjspui/handle/1/12314
DOI: 10.2217/fon.14.84
URL: http://www.ncbi.nlm.nih.gov/pubmed/25052755
Type: Journal Article
Subjects: checkpoint inhibitors
combination treatments
immunotherapy
melanoma
tumor antigens
Adaptive Immunity
Antigens, Neoplasm.immunology.metabolism
Cancer Vaccines
Humans
Immunomodulation
Immunotherapy, Adoptive
Melanoma.immunology.metabolism.therapy
Tumor Escape.immunology
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.